These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31505087)

  • 1. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
    Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
    Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
    Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
    Makino Y; Watanabe M; Makihara RA; Nokihara H; Yamamoto N; Ohe Y; Sugiyama E; Sato H; Hayashi Y
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):259-64. PubMed ID: 26948073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
    Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
    Hamada A
    Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
    Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
    Takakuwa O; Oguri T; Uemura T; Kunii E; Nakao M; Hijikata H; Kawaguchi Y; Ohkubo H; Takemura M; Maeno K; Niimi A
    Anticancer Res; 2014 Jul; 34(7):3517-22. PubMed ID: 24982363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
    Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
    Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
    Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
    Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
    Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
    Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
    J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
    Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
    Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.